Targeted therapy in NSCLC driven by HER2 insertions.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• HER2 mutations, primarily exon 20 in-frame insertions, are identified as oncogenic drivers in 1-4% of non-small cell lung cancer (NSCLC) cases.
• These mutations are exclusively found in adenocarcinoma histology, and their prognostic significance remains undetermined.
• HER2 deregulation through overexpression or amplification has shown limited clinical relevance, with only a small subset of patients benefiting from trastuzumab therapy.

Purpose of the Study:

• To investigate the role of HER2 mutations as oncogenic drivers in NSCLC.
• To evaluate the prognostic implication of HER2 alterations in NSCLC.
• To review the existing data on targeted therapies for HER2-mutated NSCLC and identify gaps in knowledge.

Main Methods:

• Review of Phase I and II trial data for HER2-mutated NSCLC.
• Analysis of literature on HER2 deregulation (overexpression/amplification) in NSCLC.
• Identification of available targeted therapies and assessment of their activity in this molecular subgroup.

Main Results:

• Phase I and II trials indicate some activity for afatinib, neratinib, and dacomitinib in HER2-mutated NSCLC.
• No comparative data exists for these or other agents like pertuzumab or trastuzumab-emtansine.
• Trastuzumab shows benefit only in a small subpopulation (2-6%) with high HER2 overexpression, predominantly in adenocarcinomas.

Conclusions:

• HER2 mutations represent a distinct molecular subset in NSCLC, predominantly adenocarcinomas.
• Current targeted therapies show limited but present activity, necessitating further investigation and comparative studies.
• The prognostic impact of HER2 mutations and the efficacy of various HER2-targeted agents require further elucidation.